EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Purinergic P2X7 Receptor as a Target for Adjunctive Treatment for Drug-Refractory Epilepsy

Divyeshz Thakku Sivakumar iD, Krishi Jain, Noura Alfehaid, Yitao Wang iD, Xinchen Teng, Wolfgang Fischer, Tobias Engel iD

International Journal of Molecular Sciences · 23.06.2024 · 25 (13) · 6894

DOI: 10.3390/ijms25136894 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 23.06.2024. Verfasst von Divyeshz Thakku Sivakumar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, University of Medicine and Health Sciences, D02 YN77 Dublin, Irel…. Hauptthemen laut MEDLINE: Receptors, Purinergic P2X7, Anticonvulsants, Purinergic P2X Receptor Antagonists, Drug Resistant Epilepsy. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 170 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science Foundation Ireland, National Natural Science Foundation of China, European Regional Development Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epilepsy is one of the most common neurological diseases worldwide. Anti-seizure medications (ASMs) with anticonvulsants remain the mainstay of epilepsy treatment. Currently used ASMs are, however, ineffective to suppress seizures in about one third of all patients. Moreover, ASMs show no significant impact on the pathogenic mechanisms involved in epilepsy development or disease progression and may cause serious side-effects, highlighting the need for the identification of new drug targets for a more causal therapy. Compelling evidence has demonstrated a role for purinergic signalling, including the nucleotide adenosine 5′-triphosphate (ATP) during the generation of seizures and epilepsy. Consequently, drugs targeting specific ATP-gated purinergic receptors have been suggested as promising treatment options for epilepsy including the cationic P2X7 receptor (P27XR). P2X7R protein levels have been shown to be increased in the brain of experimental models of epilepsy and in the resected brain tissue of patients with epilepsy. Animal studies have provided evidence that P2X7R blocking can reduce the severity of acute seizures and the epileptic phenotype. The current review will provide a brief summary of recent key findings on P2X7R signalling during seizures and epilepsy focusing on the potential clinical use of treatments based on the P2X7R as an adjunctive therapeutic strategy for drug-refractory seizures and epilepsy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Purinergic P2X7AnticonvulsantsPurinergic P2X Receptor AntagonistsDrug Resistant EpilepsyHumansAnimalsSignal TransductionMolecular Targeted TherapyEpilepsySeizures

Stichwörter der Autor:innen

P2X7 receptoradjunctive treatmentdrug-refractorinessepilepsypurinergic signallingseizures

Substanzen

Receptors, Purinergic P2X7AnticonvulsantsPurinergic P2X Receptor Antagonists

Autor:innen und Institutionen

  • Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, University of Medicine and Health Sciences, D02 YN77 Dublin, Ireland.
  • International College of Pharmaceutical Innovation, Soochow University, Suzhou 215123, China.
  • Independent Researcher, 04275 Leipzig, Germany.
  • FutureNeuro, Science Foundation Ireland Research Centre for Chronic and Rare Neurological Diseases, Royal College of Surgeons in Ireland, University of Medicine and Health Sciences, D02 YN77 Dublin, Ireland.

ORCID-Profile: Divyeshz Thakku Sivakumar, Yitao Wang, Tobias Engel

Förderung

  • Science Foundation Ireland
  • National Natural Science Foundation of China
  • European Regional Development Fund

Zitieren

APA

Thakku Sivakumar, D., Jain, K., Alfehaid, N., Wang, Y., Teng, X., Fischer, W., & Engel, T. (2024). The Purinergic P2X7 Receptor as a Target for Adjunctive Treatment for Drug-Refractory Epilepsy. International Journal of Molecular Sciences, 25(13), 6894. https://doi.org/10.3390/ijms25136894

Vancouver

Thakku Sivakumar D, Jain K, Alfehaid N, Wang Y, Teng X, Fischer W, et al. The Purinergic P2X7 Receptor as a Target for Adjunctive Treatment for Drug-Refractory Epilepsy. International Journal of Molecular Sciences. 2024;25(13):6894. doi:10.3390/ijms25136894

BibTeX
@article{ThakkuSivakumar2024,
  author = {Thakku Sivakumar, Divyeshz and Jain, Krishi and Alfehaid, Noura and Wang, Yitao and Teng, Xinchen and Fischer, Wolfgang and Engel, Tobias},
  title = {The Purinergic P2X7 Receptor as a Target for Adjunctive Treatment for Drug-Refractory Epilepsy},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {13},
  pages = {6894},
  doi = {10.3390/ijms25136894}
}
Kostenlos starten →